The relative expression of AR proved to be an important differential marker of prostate malignancy, since the results obtained from the relative expression of AR in patients with prostate cancer presented an expression above 20% (point of 1.2) compared to the patients with benign prostatic hyperplasia. This evidence concerns the gene AR and prostate carcinoma.